NIH-funded research Sbir 2 grant

Creating a new treatment for traumatic brain injury

Official title: Development of a novel peptide therapeutic for traumatic brain injury

Funded at Aivocode, LLP · NIH-10814998 · Data updated 2026-11-12

This study is testing a new treatment called CAQK to help people with moderate to severe traumatic brain injuries heal better and faster by giving it to them soon after the injury happens.

Quick facts

Grant typeSbir 2 grant
Study typeNIH-funded research
Funding institutionAivocode, LLP
NIH-funded
Lab location1 site (Encinitas, UNITED STATES)
Project startApril 1, 2023
Project endMarch 31, 2026
Funding year2024
Award (this year)$1,193,627
NIH project number5R44NS130776-02
Project IDNIH-10814998 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals who have experienced moderate to severe traumatic brain injuries.

Less likely to help

Patients with mild traumatic brain injuries or those who have not sustained a brain injury may not benefit from this research.

What this research studies

This research focuses on developing a novel peptide therapeutic called CAQK for treating moderate to severe traumatic brain injury (TBI). The approach involves administering this peptide early after the injury to limit secondary damage and promote healing. The research will conduct efficacy studies in pig models of TBI and generate pharmacokinetic profiles to understand how the treatment works in the body. The goal is to establish a new neuroprotective intervention that could significantly improve recovery outcomes for patients with TBI.

Why it matters

Potential benefit: If successful, this research could provide a new treatment option that significantly improves recovery and healing for patients suffering from traumatic brain injuries.

How similar studies have gone: While the specific peptide CAQK is novel, similar approaches targeting secondary injury in TBI have shown promise in preclinical studies.

Where this research is happening

  • Aivocode, LLP
    Encinitas, United States
    Active

Researchers

  • Principal investigator: Mann, Aman — Aivocode, LLP
  • Study coordinator: Mann, Aman

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.